Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131


Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors.

Nieto-Jiménez C, Alcaraz-Sanabria A, Pérez-Peña J, Corrales-Sánchez V, Serrano-Heras G, Galán-Moya EM, Serrano-Oviedo L, Montero JC, Burgos M, Llopis J, Pandiella A, Ocaña A.

Oncotarget. 2017 Mar 21;8(12):19478-19490. doi: 10.18632/oncotarget.14465.


Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK).

Uckun FM, Dibirdik I, Qazi S, Vassilev A, Ma H, Mao C, Benyumov A, Emami KH.

Bioorg Med Chem. 2007 Jan 15;15(2):800-14. Epub 2006 Oct 26.


Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines.

Schwermer M, Dreesmann S, Eggert A, Althoff K, Steenpass L, Schramm A, Schulte JH, Temming P.

Clin Exp Ophthalmol. 2017 Apr;45(3):288-296. doi: 10.1111/ceo.12838. Epub 2016 Nov 10.


In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment.

Pérez-Peña J, Serrano-Heras G, Montero JC, Corrales-Sánchez V, Pandiella A, Ocaña A.

Mol Cancer Ther. 2016 Aug;15(8):1823-33. doi: 10.1158/1535-7163.MCT-16-0004. Epub 2016 Jun 2.


Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery.

Strebhardt K, Becker S, Matthess Y.

Expert Opin Drug Discov. 2015 Jan;10(1):1-8. doi: 10.1517/17460441.2015.962510. Epub 2014 Sep 29.


Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition.

Kreis NN, Louwen F, Zimmer B, Yuan J.

Oncotarget. 2015 Mar 30;6(9):6611-26.


Bcl-2 degradation is an additional pro-apoptotic effect of polo-like kinase inhibition in cholangiocarcinoma cells.

Sydor S, Jafoui S, Wingerter L, Swoboda S, Mertens JC, Gerken G, Canbay A, Paul A, Fingas CD.

World J Gastroenterol. 2017 Jun 14;23(22):4007-4015. doi: 10.3748/wjg.v23.i22.4007.


Mitotic Vulnerability in Triple-Negative Breast Cancer Associated with LIN9 Is Targetable with BET Inhibitors.

Sahni JM, Gayle SS, Webb BM, Weber-Bonk KL, Seachrist DD, Singh S, Sizemore ST, Restrepo NA, Bebek G, Scacheri PC, Varadan V, Summers MK, Keri RA.

Cancer Res. 2017 Oct 1;77(19):5395-5408. doi: 10.1158/0008-5472.CAN-17-1571. Epub 2017 Aug 14.


Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73.

Wong SW, Tiong KH, Kong WY, Yue YC, Chua CH, Lim JY, Lee CY, Quah SI, Fow C, Chung C, So I, Tan BS, Choo HL, Rosli R, Cheong SK, Leong CO.

Breast Cancer Res Treat. 2011 Jul;128(2):301-13. doi: 10.1007/s10549-010-1055-0. Epub 2010 Aug 5.


Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity and Synergy with Vincristine in Pediatric Malignancies.

Abbou S, Lanvers-Kaminsky C, Daudigeos-Dubus E, LE Dret L, Laplace-Builhe C, Molenaar J, Vassal G, Geoerger B; within the ITCC Biology and Preclinical Evaluation Committee.

Anticancer Res. 2016 Feb;36(2):599-609.


Epigenetic modulation of FOXM1-gene interacting network by BET inhibitors in breast cancer.

Pérez-Peña J, Győrffy B, Amir E, Pandiella A, Ocaña A.

Breast Cancer Res Treat. 2018 Dec;172(3):725-732. doi: 10.1007/s10549-018-4965-x. Epub 2018 Sep 11.


Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.

Nihal M, Stutz N, Schmit T, Ahmad N, Wood GS.

Cell Cycle. 2011 Apr 15;10(8):1303-11. Epub 2011 Apr 15.


Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.

Spartà AM, Bressanin D, Chiarini F, Lonetti A, Cappellini A, Evangelisti C, Evangelisti C, Melchionda F, Pession A, Bertaina A, Locatelli F, McCubrey JA, Martelli AM.

Cell Cycle. 2014;13(14):2237-47. doi: 10.4161/cc.29267. Epub 2014 May 29.


Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells.

Borbely G, Haldosen LA, Dahlman-Wright K, Zhao C.

Oncotarget. 2015 Oct 20;6(32):33623-35. doi: 10.18632/oncotarget.5601.


Inhibition of BET bromodomain targets genetically diverse glioblastoma.

Cheng Z, Gong Y, Ma Y, Lu K, Lu X, Pierce LA, Thompson RC, Muller S, Knapp S, Wang J.

Clin Cancer Res. 2013 Apr 1;19(7):1748-59. doi: 10.1158/1078-0432.CCR-12-3066. Epub 2013 Feb 12.


Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors.

Ceribelli M, Kelly PN, Shaffer AL, Wright GW, Xiao W, Yang Y, Mathews Griner LA, Guha R, Shinn P, Keller JM, Liu D, Patel PR, Ferrer M, Joshi S, Nerle S, Sandy P, Normant E, Thomas CJ, Staudt LM.

Proc Natl Acad Sci U S A. 2014 Aug 5;111(31):11365-70. doi: 10.1073/pnas.1411701111. Epub 2014 Jul 21.


Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer.

Maire V, Némati F, Richardson M, Vincent-Salomon A, Tesson B, Rigaill G, Gravier E, Marty-Prouvost B, De Koning L, Lang G, Gentien D, Dumont A, Barillot E, Marangoni E, Decaudin D, Roman-Roman S, Pierré A, Cruzalegui F, Depil S, Tucker GC, Dubois T.

Cancer Res. 2013 Jan 15;73(2):813-23. doi: 10.1158/0008-5472.CAN-12-2633. Epub 2012 Nov 9.


Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology.

Schöffski P.

Oncologist. 2009 Jun;14(6):559-70. doi: 10.1634/theoncologist.2009-0010. Epub 2009 May 27. Review.

Supplemental Content

Support Center